DPP4 and type 2 diabetes mellitus: The potency of different DPP-4 inhibitors such as vildagliptin, saxagliptin, and sitagliptin has been studied in randomized clinical trials in type 2 diabetes patients and a significant improvement in glycaemic control has been observed without differences between the different drugs, suggesting that their antihyperglycaemic potency constitutes a pharmacological class effect [33].